AbbVie raises annual profit forecast as immunology drugs fuel growth
AbbVie (ABBV) raised its annual profit forecast after topping Wall Street expectations for the third quarter, driven by booming demand for its newer immunology and brain disease drugs. Its shares rose 1 percent.
